AI and NLP in Global Literature Surveillance for Pharmacovigilance

In the evolving landscape of healthcare and drug safety, pharmacovigilance (PV) plays a pivotal role in ensuring that adverse drug reactions (ADRs) are identified, reported, and mitigated. Among the many tools and technologies propelling PV into the digital age, Natural Language Processing (NLP) and Artificial Intelligence (AI) are at the forefront. One emerging player making significant strides in this space is a company leveraging AI-driven solutions to transform global literature surveillance for pharmacovigilance.

This blog delves into how is integrating NLP technologies to enhance global literature monitoring, streamline pharmacovigilance workflows, and reduce the burden of manual review — ultimately improving patient safety and regulatory compliance across the pharmaceutical industry.

The Role of Literature Surveillance in Pharmacovigilance

Pharmacovigilance requires continuous monitoring of all sources of information that may relate to the safety of pharmaceutical products. Among these sources, scientific literature — including journals, conference proceedings, case reports, and databases — serves as a critical repository of emerging safety data.

Regulatory agencies such as the FDA (U.S.), EMA (Europe), and MHRA (UK) mandate that marketing authorization holders (MAHs) regularly review indexed scientific literature for any information on ADRs, special situations (like medication errors), or off-label usage that could impact a drug's safety profile.

Global literature surveillance (GLS), however, poses several challenges:

• High volume of data: Thousands of journals and millions of articles are published annually.

• Language diversity: Important information may be published in non-English sources.

• Complexity of clinical language: Extracting relevant safety data requires expertise and nuance.

• Manual labor: Traditional surveillance is labor-intensive and prone to human error.

This is where AI and NLP come into play — and where companies like  are reshaping the pharmacovigilance landscape.

Enter: Revolutionizing PV with AI

Founded with a mission to apply state-of-the-art AI to real-world healthcare problems, focuses on automating complex cognitive workflows using deep learning and NLP. Their solutions are designed specifically to tackle the burdensome and error-prone aspects of pharmacovigilance, starting with literature surveillance.

What is 47.AI?

47.AI is an AI-first platform offering cognitive automation tools for regulated industries. In the pharmacovigilance context, the company provides an end-to-end literature monitoring solution powered by NLP and machine learning to automatically:

• Scan global literature sources

• Identify relevant safety information

• Extract entities like drug names, reactions, patient information

• Support regulatory reporting processes (e.g., ICSR generation)

NLP in Pharmacovigilance: Core Capabilities

Natural Language Processing, a subfield of AI, focuses on enabling machines to understand and interpret human language. In pharmacovigilance, NLP is used to process unstructured text (e.g., journal articles, case studies) and extract structured information relevant for safety assessments.

47.AI leverages several key NLP techniques:

1. Named Entity Recognition (NER)

NER is used to identify and classify critical entities such as:

• Drug names (both brand and generic)

• Adverse drug reactions (based on MedDRA terms)

• Patient demographics

• Indications, comorbidities, and outcomes

47.AI’s models are trained specifically for the biomedical and regulatory context, ensuring high precision and recall even in noisy or ambiguous text.

2. Document Classification

To reduce the workload for PV teams, 47.AI’s solution first classifies documents based on their relevance:

• Does the article mention an ICSR-eligible case?

• Is the drug of interest discussed in a clinical context?

• Does the content relate to off-label use, overdose, or pregnancy exposure?

Advanced classifiers powered by deep learning ensure that only truly relevant documents move forward in the workflow.

3. Relation Extraction

Once entities are identified, NLP algorithms determine how they are related. For example:

• Is the reported reaction causally linked to the drug?

• Was the drug administered before or after the reaction?

• What was the severity or outcome of the event?

Relation extraction is key for building structured case reports (ICSRs) suitable for submission to health authorities.

4. Language Translation & Multilingual NLP

Global literature isn’t limited to English. integrates multilingual NLP and machine translation to process non-English documents, expanding the reach of surveillance efforts without increasing staffing needs.

The Literature Surveillance Workflow

offers a fully integrated literature monitoring pipeline that automates the end-to-end process, allowing PV teams to shift their focus from manual review to strategic analysis.

Step 1: Source Aggregation

The system continuously ingests content from:

• Global indexing databases (e.g., PubMed, Embase)

• Local language journals

• Grey literature, preprints, and regulatory bulletins

Custom ingestion pipelines ensure full compliance with region-specific regulations.

Step 2: Preprocessing and De-duplication

Articles are preprocessed to remove duplicates, correct formatting errors, and standardize terminology using ontologies like MedDRA and WHODrug.

Step 3: NLP-Driven Screening

The AI engine reads and interprets each article, performing:

• Relevance classification

• Entity and relation extraction

• Language detection and translation if necessary

Articles that meet defined thresholds are flagged for human review, while irrelevant ones are automatically discarded or archived.

Step 4: Case Highlighting and Draft ICSR Generation

For relevant cases, auto-generates ICSR drafts by populating:

• Patient and reporter information

• Suspect and concomitant drugs

• Reaction terms

• Narrative summaries

Reviewers validate, enrich, and submit the reports with minimal manual effort.

Regulatory Compliance and Quality Assurance

In a highly regulated industry, AI tools must meet rigorous standards. incorporates:

• Audit trails: Every AI decision is traceable.

• Human-in-the-loop (HITL) validation: Safety experts can override or confirm AI output.

• GxP compliance: Systems are validated according to FDA and EMA guidelines.

• Periodic model updates: Algorithms are retrained with new data to adapt to evolving medical language and safety patterns.

Benefits for Pharma and CROs

Adopting NLP-powered literature surveillance solution can lead to transformative benefits:

1. Operational Efficiency

By automating up to 80% of literature review tasks, pharma companies can reallocate resources to higher-value safety analysis and risk management.

2. Scalability

platform can handle high-volume data streams from multiple countries and languages without additional human resources, enabling true global surveillance.

3. Improved Case Quality

AI models ensure consistent extraction of key details and reduce variability across safety reviewers.

4. Faster Reporting

Accelerated identification and triage of ICSR cases help companies meet strict regulatory timelines, such as the 15-day window for serious unexpected adverse events.

5. Cost Savings

Automating the most labor-intensive part of the PV process can significantly reduce costs related to outsourced medical writing, translation, and literature monitoring.

Challenges and Future Outlook

While the benefits are compelling, AI and NLP adoption in pharmacovigilance is not without challenges:

• Model Bias: NLP models must be carefully trained to avoid bias and ensure accuracy across diverse patient populations and publication styles.

• Edge Cases: Rare or unusual ADRs may still require expert clinical judgment beyond the reach of current algorithms.

• Change Management: Integrating AI into established PV workflows requires cultural and process adjustments, including retraining staff and adapting SOPs.

That said, the momentum is clear. As regulatory bodies begin to embrace AI tools — evidenced by initiatives like the FDA’s digital health framework and the EMA’s data analytics strategy — AI-enabled literature surveillance is quickly becoming not just a competitive advantage, but a necessity.

Conclusion

The sheer scale and complexity of global literature surveillance make it an ideal candidate for AI transformation at the cutting edge of this revolution, offering a powerful blend of NLP, deep learning, and compliance-centric design tailored to the unique needs of pharmacovigilance.

By automating the extraction of critical safety data from worldwide literature sources, enables pharmaceutical companies to protect patients more effectively, stay ahead of regulatory requirements, and drive operational efficiency.

As AI technology continues to evolve and integrate deeper into healthcare systems, tools like those from will be instrumental in shaping the future of pharmacovigilance — making it faster, smarter, and more global than ever before.

Author’s Note:If you're involved in pharmacovigilance and looking to enhance your literature monitoring capabilities, exploring AI-based tools like may be the strategic upgrade your safety operations need. The future of drug safety is intelligent — and it's already here.